Search for drugs:
Typing the drug name to query
TAFENOQUINE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effect of tafenoquine on the QT interval was evaluated in a study of healthy adult subjects. In this study, subjects received once daily 400 mg (2 times the approved recommended dosage) doses of tafenoquine for 3 days. The results suggest that the mean increase in the QTcF interval for tafenoquine is less than 20 msec.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- P01BA07 - tafenoquine
- P01BA - Aminoquinolines
- P01B - ANTIMALARIALS
- P01 - ANTIPROTOZOALS
- P - "ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS"
Active Ingredient:TAFENOQUINE
Active Ingredient UNII:262P8GS9L9
Drugbank ID:DB06608
PubChem Compound:N/ADIR Classification
CTD ID:C055852
PharmGKB:PA166115580
CAS Number:106635-80-7
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1
COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1
Reference
1: Drug interactions with antimalarial medications in older travelers: a clinical guide.
[Lewis Jelena,Gregorian Tania,Portillo Ivan,Goad Jeff]J Travel Med,2020 Feb 3;27(1):taz089. PMID: 31776555
2: Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
[Green Justin A,Mohamed Khadeeja,Goyal Navin,Bouhired Samia,Hussaini Azra,Jones Siôn W,Koh Gavin C K W,Kostov Ivan,Taylor Maxine,Wolstenholm Allen,Duparc Stephan]Antimicrob Agents Chemother,2016 Nov 21;60(12):7321-7332. PMID: 27697758
3: Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
[Llanos-Cuentas Alejandro,Lacerda Marcus V,Rueangweerayut Ronnatrai,Krudsood Srivicha,Gupta Sandeep K,Kochar Sanjay K,Arthur Preetam,Chuenchom Nuttagarn,Möhrle Jörg J,Duparc Stephan,Ugwuegbulam Cletus,Kleim Jörg-Peter,Carter Nick,Green Justin A,Kellam Lynda]Lancet,2014 Mar 22;383(9922):1049-58. PMID: 24360369
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.